Ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen in the treatment of premenstrual dysphoric disorder-related symptoms and functional impairment: a randomized, multicenter, double-blind, parallel study.
Phase of Trial: Phase III
Latest Information Update: 01 May 2011
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Premenstrual dysphoric disorder
- Focus Therapeutic Use
- Sponsors Bayer HealthCare Pharmaceuticals
- 05 Nov 2010 New trial record.